Acquisition Announced

BioMarin acquisition of Amicus Therapeutics

US$4.8bn equity value

Announced 19 Dec 2025 · US$14.50 cash per share

Advisers

Amicus Therapeutics

Target

Legal adviser

BioMarin

Acquirer

Financial adviser
Legal adviser
Target
Amicus Therapeutics
Acquirer
BioMarin
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Rare Disease, Pharma

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.